The online version of this article (doi:10.1186/1477-7819-10-82) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
RJC: case preparation and revised the manuscript. The author read and approved the final manuscript; RB: case preparation, established the imaging protocols and revised the manuscript; BG: revised the manuscript; AT: revised the manuscript; FC: case preparation, drafted discussion and revised the manuscript. FC: is member of the advisor board member for the European Neuroendocrine Tumor Society. All the authors read and approved the final manuscript.
Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey J-N, Rashid A, Evans DB: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26: 3063-3072. 10.1200/JCO.2007.15.4377. CrossRefPubMed
McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS: Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990, 108: 1091-1096. PubMed
Gourtsoyianni S, Papanikolaou N, Yarmenitis S, Maris T, Karantanas A, Gourtsoyiannis N: Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol. 2008, 18: 486-492. 10.1007/s00330-007-0798-4. CrossRefPubMed
Liapi E, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA, Kamel IR: Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008, 190: 67-73. 10.2214/AJR.07.2550. CrossRefPubMed
Anaye A, Mathieu A, Closset J, Bali MA, Metens T, Matos C: Successful preoperative localization of a small pancreatic insulinoma by diffusion-weighted MRI. JOP. 2009, 10: 528-531. PubMed
Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, Ceccarelli C, Nori F, Franchi R, Corinaldesi R, Tomassetti P: Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010, 51: 353-359. 10.2967/jnumed.109.066662. CrossRefPubMed
Laurent V, Trausch G, Bruot O, Olivier P, Felblinger J, Régent D: Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT. Eur J Radiol. 2010, 75: 376-383. 10.1016/j.ejrad.2009.04.059. CrossRefPubMed
Takano A, Oriuchi N, Tsushima Y, Taketomi-Takahashi A, Nakajima T, Arisaka Y, Higuchi T, Amanuma M, Endo K: Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18FFDG positron emission tomography and 123I-MIBG scintigraph. Ann Nucl Med. 2008, 22: 395-401. 10.1007/s12149-008-0128-1. CrossRefPubMed
- Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases
Rachel Jorge D Cossetti
Regis Otaviano França Bezerra
Frederico P Costa
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II